This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Ma H, Marti-Gutierrez N, Park S-W, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2019;548:413–9.
Moro LN, Viale DL, Bastón JI, Arnold V, Suvá M, Wiedenmann E, et al. Generation of myostatin edited horse embryos using CRISPR/Cas9 technology and somatic cell nuclear transfer. Sci Rep. 2020;10:15587.
Cheung HW, Wong KS, Lin VYC, Wan TSM, Ho ENM. A duplex qPCR assay for human erythropoietin (EPO) transgene to control gene doping in horses. Drug Test Anal. 2020;13:113–21.
Sugasawa T, Aoki K, Yanazawa K, Takekoshi K. Detection of multiple transgene fragments in a mouse model of gene doping based on plasmid vector using TaqMan-qPCR assay. Genes. 2020;11:750.
Moser DA, Braga L, Raso A, Zacchigna S, Giacca M, Simon P. Transgene detection by digital droplet PCR. PLoS One. 2014;9:e111781.
Tozaki T, Ohnuma A, Kikuchi M, Ishige T, Kakoi H, Hirota KI, et al. Microfluidic Quantitative PCR Detection of 12 Transgenes from Horse Plasma for Gene Doping Control. Genes. 2020;11:457.
de Boer EN, van der Wouden PE, Johansson LF, van Diemen CC, Haisma HJ. A next-generation sequencing method for gene doping detection that distinguishes low levels of plasmid DNA against a background of genomic DNA. Gene Ther. 2019;26:338–46.
Hirsch ML, Wolf SJ, Samulski RJ. Delivering transgenic DNA exceeding the carrying capacity of AAV vectors. Methods Mol Biol. 2016;1382:21–39.
Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157:137–47.
Lippin Y, Dranitzki-Elhalel M, Brill-Almon E, Mei-Zahav C, Mizrachi S, Liberman Y, et al. Human erythropoietin gene therapy for patients with chronic renal failure. Blood. 2005;106:2280–6.
Song Y-H, Song JL, Delafontaine P, Godard M. The therapeutic potential of IGF-I in skeletal muscle repair. Trends Endocrinol Metab. 2013;24:310–9.
Martier R, Liefhebber JM, García-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, et al. Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy. Mol Ther Nucleic Acids. 2019;16:26–37.
Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, et al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol. 2019;266:2129–36.
Hill EW, Gu J, Eivers SS, Fonseca RG, McGivney BA, Govindarajan P, et al. A sequence polymorphism in MSTN predicts sprinting ability and racing stamina in thoroughbred horses. PLoS One. 2010;5:e8645.
Bayarsaikhan O, Kawai N, Mori H, Kinouchi N, Nikawa T, Tanaka E. Co-administration of myostatin-targeting siRNA and ActRIIB-Fc fusion protein increases masseter muscle mass and fiber size. J Nutr Sci Vitaminol. 2017;63:244–8.
Khan T, Weber H, DiMuzio J, Matter A, Dogdas B, Shah T, et al. Silencing Myostatin using cholesterol-conjugated siRNAs induces muscle growth. Mol Ther Nucleic Acids. 2016;5:e342.
Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–21.
Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 2018;36:765–71.
Pradhan A, Kalin TV, Kalinichenko VV. Genome editing for rare diseases. Curr Stem Cell Rep. 2020;6:41–51.
Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25:1234–57.
Kimberland ML, Hou W, Alfonso-Pecchio A, Wilson S, Rao Y, Zhang S, et al. Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments. J Biotechnol. 2018;284:91–101.
Tozaki T, Ohnuma A, Takasu M, Kikuchi M, Kakoi H, Hirota KI, et al. Droplet digital PCR detection of the erythropoietin transgene from horse plasma and urine for gene-doping control. Genes. 2019;10:243.
Tozaki T, Gamo S, Takasu M, Kikuchi M, Kakoi H, Hirota K, et al. Digital PCR detection of plasmid DNA administered to the skeletal muscle of a microminipig: a model case study for gene doping detection. BMC Res Notes. 2018;11:708.
Ni W, Guiner CL, Gernoux G, Penaud-Budloo M, Moullier P, Snyder RO. Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping. Gene Ther. 2011;18:709–18.
Beiter T, Zimmermann M, Fragasso A, Hudemann J, Niess AM, Bitzer M, et al. Direct and long-term detection of gene doping in conventional blood samples. Gene Ther. 2011;18:225–31.
Baoutina A, Coldham T, Fuller B, Emslie KR. Improved detection of transgene and nonviral vectors in blood. Hum Gene Ther Methods. 2013;24:345–54.
Tozaki T, Ohnuma A, Takasu M, Nakamura K, Kikuchi M, Ishige T, et al. Detection of non-targeted transgenes by whole-genome resequencing for gene-doping control. Gene Ther. 2021;28:199–205.
Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28:333–9.
Tozaki T, Karasawa K, Minamijima Y, Ishii H, Kikuchi M, Kakoi H, et al. Detection of phosphorothioated (PS) oligonucleotides in horse plasma using a product ion (m/z 94.9362) derived from the PS moiety for doping control. BMC Res Notes. 2018;11:770.
Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24:374–87.
Paßreiter A, Thomas A, Grogna N, Delahaut P, Thevis M. First steps toward uncovering gene doping with CRISPR/Cas by identifying SpCas9 in plasma via HPLC−HRMS/MS. Anal Chem. 2020;92:16322–8.
Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B, et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood. 2004;103:3300–2.
Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood. 2004;103:3303–4.
Campbell MLH, McNamee MJ. Ethics, genetic technologies and equine sports: the prospect of regulation of a modified therapeutic use exemption policy. Sport Ethics Philos. 2020. https://doi.org/10.1080/17511321.2020.1737204.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tozaki, T., Hamilton, N.A. Control of gene doping in human and horse sports. Gene Ther 29, 107–112 (2022). https://doi.org/10.1038/s41434-021-00267-5